<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73850">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01886443</url>
  </required_header>
  <id_info>
    <org_study_id>CAPITL safety</org_study_id>
    <nct_id>NCT01886443</nct_id>
  </id_info>
  <brief_title>Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers</brief_title>
  <acronym>CAPITL</acronym>
  <official_title>Phase 1 Safety Study of Combined Drug Approach to Prevent Ischemia-reperfusion Injury During Transplantation of Livers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <authority>Belgium: Federal Agency for Medicines and Health Products, FAMHP</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety of the combined drug approach
      (anti-thrombin III, infliximab, apotransferrin, human recombinant erythropoietin beta,
      C1-inhibitor, glutathione, alfa-tocopherol, melatonin and epoprostenol)aimed to reduce
      ischemia-reperfusion injury during liver transplantation in eligible recipients.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>During and within the 7 days following the liver transplantation</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antithrombin-III</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Infliximab</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apotransferrin</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human recombinant erythropoietin</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>C1-Inhibitor</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glutathione</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alfa-tocopherol</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melatonin</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epoprostenol</intervention_name>
    <arm_group_label>Combined drug approach, safety study</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients suffering from irreversible liver failure eligible for liver transplantation
             according to Eurotransplant guidelines.

          2. Patients &gt; 18 years of age at time of listing on Eurotransplant waiting list for
             liver transplantation in University Hospitals Leuven, Belgium.

        Exclusion Criteria:

          1. Patients who refuse to participate in the study.

          2. History of hypersensitivity to one/several component(s) of the combined drug
             approach.

          3. Conditions that prevent the use of the combined drug approach:

               -  Administration of heparin at therapeutic dose pre-operatively,

               -  Congestive heart failure,

               -  Pre-operative level of hemoglobin higher than 13 mg/dl,

               -  History of seizure, poorly controlled arterial hypertension, myocardial
                  infarction or stroke in the month preceding the liver transplantation, venous
                  thromboembolic disease,

               -  Unstable angina pectoris,

               -  Sepsis, abcesses or opportunistic infections,

               -  History of infliximab treatment,

               -  Use of vitamin K antagonist anticoagulation.

          4. Mental conditions rendering the subject incapable to understand the nature, scope,
             and consequences of the trial.

          5. Combined organ transplantation.

          6. Re-transplantation.

          7. Patients that are dialysis-dependent prior to the liver transplantation.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diethard Monbaliu, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Abdominal transplant surgery - transplant coordination, Abdominal transplant surgery lab (microbiology &amp; immunology Dpt)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diethard Monbaliu, MD, PhD</last_name>
    <email>diethard.monbaliu@uzleuven.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nicolas Meurisse, MD</last_name>
    <email>Nicolas.Meurisse@med.kuleuven.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Meurisse, MD</last_name>
      <email>Nicolas.Meurisse@med.kuleuven.be</email>
    </contact>
    <investigator>
      <last_name>Diethard Monbaliu, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques Pirenne, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas Meurisse, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Monbaliu D, Vekemans K, Hoekstra H, Vaahtera L, Libbrecht L, Derveaux K, Parkkinen J, Liu Q, Heedfeld V, Wylin T, Deckx H, Zeegers M, Balligand E, Buurman W, van Pelt J, Porte RJ, Pirenne J. Multifactorial biological modulation of warm ischemia reperfusion injury in liver transplantation from non-heart-beating donors eliminates primary nonfunction and reduces bile salt toxicity. Ann Surg. 2009 Nov;250(5):808-17. doi: 10.1097/SLA.0b013e3181bdd787.</citation>
    <PMID>19826248</PMID>
  </reference>
  <reference>
    <citation>Vekemans K, Monbaliu D, Balligand E, Heedfeld V, Jochmans I, Pirenne J, van Pelt J. Improving the function of liver grafts exposed to warm ischemia by the Leuven drug protocol: exploring the molecular basis by microarray. Liver Transpl. 2012 Feb;18(2):206-18. doi: 10.1002/lt.22446.</citation>
    <PMID>21987442</PMID>
  </reference>
  <verification_date>June 2013</verification_date>
  <lastchanged_date>September 9, 2013</lastchanged_date>
  <firstreceived_date>June 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liver</keyword>
  <keyword>Transplantation</keyword>
  <keyword>Ischemia-reperfusion</keyword>
  <keyword>Safety</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antithrombins</mesh_term>
    <mesh_term>Antithrombin III</mesh_term>
    <mesh_term>Antithrombin Proteins</mesh_term>
    <mesh_term>Epoetin Alfa</mesh_term>
    <mesh_term>Epoprostenol</mesh_term>
    <mesh_term>Melatonin</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Alpha-Tocopherol</mesh_term>
    <mesh_term>Tezosentan</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
